Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

transplantation National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine research support non-u.s. gov't adult female male middle aged Comparative Study risk factors Clinical Trial Phase III Randomized Controlled Trial Antibodies Monoclonal Multicenter Study follow-up studies survival rate autologous induction chemotherapy pmid:28668386 doi:10.1016/s1470-2045(17)30444-8 annalisa chiappella maurizio martelli umberto vitolo murine-derived / administration & dosage murine-derived / adverse effects antineoplastic combined chemotherapy protocols / administration & dosage* antineoplastic combined chemotherapy protocols / adverse effects carmustine / administration & dosage consolidation chemotherapy cyclophosphamide / administration & dosage cyclophosphamide / adverse effects cytarabine / administration & dosage dexamethasone / administration & dosage disease-free survival doxorubicin / administration & dosage doxorubicin / adverse effects etoposide / administration & dosage hematologic diseases / chemically induced intention to treat analysis lymphoma large b-cell diffuse / therapy* melphalan / administration & dosage mitoxantrone / administration & dosage prednisone / administration & dosage prednisone / adverse effects rituximab / administration & dosage* stem cell transplantation* / adverse effects vincristine / administration & dosage vincristine / adverse effects